<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mesoblast Ltd — News on 6ix</title>
<link>https://6ix.com/company/mesoblast-ltd</link>
<description>Latest news and press releases for Mesoblast Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 04:11:04 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mesoblast-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836661a78dffbe2df15dcf0.webp</url>
<title>Mesoblast Ltd</title>
<link>https://6ix.com/company/mesoblast-ltd</link>
</image>
<item>
<title>Patient Recruitment Target Achieved in CLBP Pivotal Trial</title>
<link>https://6ix.com/company/mesoblast-ltd/news/patient-recruitment-target-achieved-in-clbp-pivotal-trial</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/patient-recruitment-target-achieved-in-clbp-pivotal-trial</guid>
<pubDate>Wed, 29 Apr 2026 04:11:04 GMT</pubDate>
<description>Patient Recruitment Target Achieved in CLBP Pivotal Trial</description>
</item>
<item>
<title>Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-achieves-patient-recruitment-target-in-pivotal-phase-3-trial-for-chronic-low-back-pain</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-achieves-patient-recruitment-target-in-pivotal-phase-3-trial-for-chronic-low-back-pain</guid>
<pubDate>Wed, 29 Apr 2026 00:53:00 GMT</pubDate>
<description>NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary all</description>
</item>
<item>
<title>Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-acquires-chimeric-antigen-receptor-car-platform-technology-for-precision-enhanced-cell-products</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-acquires-chimeric-antigen-receptor-car-platform-technology-for-precision-enhanced-cell-products</guid>
<pubDate>Wed, 15 Apr 2026 00:10:00 GMT</pubDate>
<description>NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products</description>
</item>
<item>
<title>Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncilr-in-duchenne-muscular-dystrophy-correction</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncilr-in-duchenne-muscular-dystrophy-correction</guid>
<pubDate>Fri, 10 Apr 2026 20:09:00 GMT</pubDate>
<description>Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrati</description>
</item>
<item>
<title>Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-randd-day-features-significant-commercial-progress-and-platform-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-randd-day-features-significant-commercial-progress-and-platform-innovation</guid>
<pubDate>Wed, 08 Apr 2026 13:07:00 GMT</pubDate>
<description>Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for inflammatory back pain and heart failure Announces close of enrollment for Phase 3 trial for CLBP at the end of this month Highlights label extension strategy for Ryoncil® in adult and pediatric rare diseases: - Adult SR-aGvHD trial cleared by central institutional review board (IRB), first sites to be activate</description>
</item>
<item>
<title>Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncilr-in-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-receives-ind-clearance-from-fda-to-directly-proceed-to-registrational-trial-for-approval-of-ryoncilr-in-duchenne-muscular-dystrophy</guid>
<pubDate>Wed, 08 Apr 2026 03:35:00 GMT</pubDate>
<description>Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical tria</description>
</item>
<item>
<title>Ryoncil Net Revenue for the Quarter Increases to US$30.3M</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncil-net-revenue-for-the-quarter-increases-to-usdollar303m</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncil-net-revenue-for-the-quarter-increases-to-usdollar303m</guid>
<pubDate>Tue, 07 Apr 2026 04:33:03 GMT</pubDate>
<description>Ryoncil Net Revenue for the Quarter Increases to US$30.3M</description>
</item>
<item>
<title>Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncilr-continues-successful-first-year-launch-with-net-sales-of-usdollar303m-in-march-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncilr-continues-successful-first-year-launch-with-net-sales-of-usdollar303m-in-march-quarter</guid>
<pubDate>Tue, 07 Apr 2026 01:03:00 GMT</pubDate>
<description>Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of</description>
</item>
<item>
<title>Mesoblast to Host R&D Day on April 8, 2026</title>
<link>https://6ix.com/company/mesoblast-ltd/news/mesoblast-to-host-randd-day-on-april-8-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/mesoblast-to-host-randd-day-on-april-8-2026</guid>
<pubDate>Tue, 17 Mar 2026 23:19:00 GMT</pubDate>
<description>NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders. The event will include discussions regarding the company’s corporate strategy, successful commercializ</description>
</item>
<item>
<title>Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast</title>
<link>https://6ix.com/company/mesoblast-ltd/news/dr-teresa-montagut-appointed-as-clinical-development-and-medical-affairs-head-at-mesoblast</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/dr-teresa-montagut-appointed-as-clinical-development-and-medical-affairs-head-at-mesoblast</guid>
<pubDate>Wed, 11 Mar 2026 23:21:00 GMT</pubDate>
<description>NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast’s medical affairs organization, fostering clinical collaborations and spearheading investigator-ini</description>
</item>
<item>
<title>Ryoncil Profits Underpinning Substantial Growth Pipeline</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncil-profits-underpinning-substantial-growth-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncil-profits-underpinning-substantial-growth-pipeline</guid>
<pubDate>Fri, 27 Feb 2026 03:23:25 GMT</pubDate>
<description>Ryoncil Profits Underpinning Substantial Growth Pipeline</description>
</item>
<item>
<title>Corporate Presentation and Half Year Financial Results</title>
<link>https://6ix.com/company/mesoblast-ltd/news/corporate-presentation-and-half-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/corporate-presentation-and-half-year-financial-results</guid>
<pubDate>Fri, 27 Feb 2026 03:10:11 GMT</pubDate>
<description>Corporate Presentation and Half Year Financial Results</description>
</item>
<item>
<title>Half Year Report and Accounts (including Appendix 4D)</title>
<link>https://6ix.com/company/mesoblast-ltd/news/half-year-report-and-accounts-including-appendix-4d</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/half-year-report-and-accounts-including-appendix-4d</guid>
<pubDate>Fri, 27 Feb 2026 03:03:20 GMT</pubDate>
<description>Half Year Report and Accounts (including Appendix 4D)</description>
</item>
<item>
<title>Ryoncil® Profits Underpinning Substantial Growth Pipeline</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncilr-profits-underpinning-substantial-growth-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncilr-profits-underpinning-substantial-growth-pipeline</guid>
<pubDate>Fri, 27 Feb 2026 00:42:00 GMT</pubDate>
<description>Financial Results and Operational Update for Half-Year Ended December 31, 2025NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2</description>
</item>
<item>
<title>High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD</title>
<link>https://6ix.com/company/mesoblast-ltd/news/high-survival-rates-ryoncil-eind-232700876</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/high-survival-rates-ryoncil-eind-232700876</guid>
<pubDate>Wed, 11 Feb 2026 23:27:00 GMT</pubDate>
<description>NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah. The study results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in stero</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/mesoblast-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-2</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-2</guid>
<pubDate>Thu, 29 Jan 2026 04:26:03 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Ryoncil® Net Revenues Increase for the Quarter to US$30M</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncil-net-revenues-increase-quarter-235400672</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncil-net-revenues-increase-quarter-235400672</guid>
<pubDate>Wed, 28 Jan 2026 23:54:00 GMT</pubDate>
<description>Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. “This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater f</description>
</item>
<item>
<title>Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment</title>
<link>https://6ix.com/company/mesoblast-ltd/news/real-world-commercial-experience-ryoncil-234500690</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/real-world-commercial-experience-ryoncil-234500690</guid>
<pubDate>Mon, 26 Jan 2026 23:45:00 GMT</pubDate>
<description>NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (</description>
</item>
<item>
<title>FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy</title>
<link>https://6ix.com/company/mesoblast-ltd/news/fda-acknowledges-effects-pain-intensity-000100776</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/fda-acknowledges-effects-pain-intensity-000100776</guid>
<pubDate>Mon, 19 Jan 2026 00:01:00 GMT</pubDate>
<description>Approval Label May Include Opioid ReductionNEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Application (BLA) for its allogeneic cell therapy product rexlemestrocel-L in patients with chronic discogenic low back pain (CLBP). This follows FDA’s Type B meeting review</description>
</item>
<item>
<title>Ryoncil Sales for the Quarter Increase 60% to US$35.1M</title>
<link>https://6ix.com/company/mesoblast-ltd/news/ryoncil-sales-for-the-quarter-increase-60percent-to-usdollar351m</link>
<guid isPermaLink="true">https://6ix.com/company/mesoblast-ltd/news/ryoncil-sales-for-the-quarter-increase-60percent-to-usdollar351m</guid>
<pubDate>Fri, 09 Jan 2026 04:18:10 GMT</pubDate>
<description>Ryoncil Sales for the Quarter Increase 60% to US$35.1M</description>
</item>
</channel>
</rss>